padrão voz ativa do verbo (occur - termo antes)

X (occurred_VBD|did_VBD occur_VB)

1. Java: ((?:[\\w-/]*_[A-Z]{2,3}\\s|,_,\\s)*)(?:occurred_VBD\\s|did_VBD occur_VB\\s)
2. Perl: ((?:[\w-/]*_[A-Z]{2,3}\s|,_,\s)*)(?:occurred_VBD\s|did_VBD occur_VB\s)
	// \w  Casa letras, dígitos, ou '_'.
	// 1 e 2 são equivalentes
	
Sentences Examples:

Recurrent_JJ stroke_NN occurred_VBD in_IN one_CD patient_NN after_IN 6_CD years_NNS of_IN follow-up_JJ despite_IN evidence_NN of_IN good_JJ compliance_NN with_IN therapy_NN as_IN assessed_VBN by_IN hematologic_JJ response_NN to_TO HU_NNP ._.

During_IN the_DT trial_NN period_NN ,_, 75_CD ACS_NNP events_NNS occurred_VBD and_CC were_VBD 2_CD times_NNS more_RBR frequent_JJ in_IN the_DT placebo_NN arm_NN -LRB-_-LRB- 51_CD events_NNS -RRB-_-RRB- than_IN in_IN the_DT HU_NNP arm_NN -LRB-_-LRB- 25_CD events_NNS -RRB-_-RRB- ._.

Hematopoietic_JJ depression_NN did_VBD occur_VB during_IN therapy_NN ,_, as_IN anticipated_VBN ,_, but_CC it_PRP was_VBD short_RB lived_VBN ._.

In_IN the_DT present_JJ study_NN we_PRP observed_VBD that_IN the_DT greatest_JJS PS_NNP exposure_NN occurred_VBD on_IN the_DT largest_JJS erythrocytes_NNS ,_, as_IN demonstrated_VBN by_IN flow_NN cytometry_NN -LRB-_-LRB- larger_JJR FSC_NNP -RRB-_-RRB- -LRB-_-LRB- Figure_NN 3_CD -RRB-_-RRB- ._.

One_CD occurred_VBD after_IN 3_CD months_NNS of_IN treatment_NN in_IN a_DT child_NN in_IN whom_WP stroke_NN was_VBD the_DT only_JJ indication_NN for_IN hydroxyurea_NN ._.

The_DT second_JJ one_CD occurred_VBD in_IN a_DT child_NN whose_WP$ past_JJ history_NN of_IN stroke_NN was_VBD not_RB the_DT reason_NN advocated_VBN by_IN his_PRP$ physician_NN for_IN hydroxyurea_NN treatment_NN ,_, this_DT reason_NN being_VBG the_DT existence_NN of_IN painful_JJ crises_NNS ._.

One_CD malignancy_NN occurred_VBD in_IN our_PRP$ cohort_NN ,_, but_CC analysis_NN of_IN this_DT case_NN led_VBD us_PRP to_TO conclude_VB that_DT ,_, most_RBS probably_RB ,_, the_DT leukemia_NN pre-existed_VBD the_DT hydroxyurea_NN administration_NN ,_, since_IN the_DT leukemia_NN was_VBD diagnosed_VBN 1.5_CD months_NNS after_IN starting_VBG hydroxyurea_NN therapy_NN ._.

Neurologic_JJ events_NNS occurred_VBD in_IN 11_CD percent_NN of_IN patients_NNS ,_, among_IN whom_WP 46_CD percent_NN had_VBD respiratory_JJ failure_NN ._.

Neurologic_JJ events_NNS occurred_VBD in_IN 11_CD percent_NN of_IN patients_NNS ._.

Anoxic_JJ brain_NN injury_NN occurred_VBD in_IN three_CD patients_NNS ,_, central_JJ nervous_JJ system_NN hemorrhage_NN in_IN three_CD ,_, and_CC infarction_NN in_IN three_CD ._.

Laryngospasm_NNP occurred_VBD in_IN 10_CD patients_NNS ,_, and_CC pneumothorax_NNS developed_VBN in_IN 2_CD patients_NNS ,_, both_DT of_IN whom_WP had_VBD had_VBN the_DT acute_JJ respiratory_JJ distress_NN syndrome_NN before_IN the_DT bronchoscopy_NN ._.

Mycoplasma_NNP and_CC viral_JJ pneumonia_NN ,_, including_VBG that_IN caused_VBN by_IN parvovirus_NN ,_, occurred_VBD in_IN all_DT age_NN groups_NNS ,_, but_CC predominated_VBD among_IN young_JJ children_NNS ._.

